Neurizon Therapeutics Limited has released a press release.
FDA Grants PharmAust Pre-IND Meeting
Filed with ASX ·
6ix hasn’t read this filing yet.
Neurizon Therapeutics Limited on 6ix
Earlier from Neurizon Therapeutics
- FightMND Invites PharmAust to Apply for Phase 2/3 Funding
- PharmAust Receives R&D Tax Incentive Refund
- 93% take up in Options Offer
- PharmAust Raises $3.5 Million at a Premium
- PAA completes Phase 1 and files for Orphan Drug Designation
Later from Neurizon Therapeutics
- PharmAust Partners with Berry Consultants for MND Phase 2/3
- FDA Provides Clear Feedback for ODD Approval
- Ethics Committee Approval for Open-Label MND Extension Study
- Extension Study Begins, Analysis Suggests Survival Benefit
- FDA Outlines Pathway to Accelerated Approval for MPL in MND
Follow Neurizon Therapeutics into a list and get an email when it puts out news.
Follow Neurizon Therapeutics